JP7204005B2 - タンパク質チロシンホスファターゼ阻害物質及びその使用方法 - Google Patents

タンパク質チロシンホスファターゼ阻害物質及びその使用方法 Download PDF

Info

Publication number
JP7204005B2
JP7204005B2 JP2021555178A JP2021555178A JP7204005B2 JP 7204005 B2 JP7204005 B2 JP 7204005B2 JP 2021555178 A JP2021555178 A JP 2021555178A JP 2021555178 A JP2021555178 A JP 2021555178A JP 7204005 B2 JP7204005 B2 JP 7204005B2
Authority
JP
Japan
Prior art keywords
alkyl
hydroxy
fluoro
trione
thiadiazolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021555178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522526A (ja
Inventor
アンドリュー ボグダン
ジェフ ティー． ハルボーセン
エリオット ピー． ファーニー
ジェニファー エム． フロスト
フィリップ アール． キム
マーク エイ． マトゥレンコ
マシュー オコナー
レザ シルーディ
エリック ヴォイト
チャオミン ション
シンウェイ チャン
クリスティーナ バウムガートナー
ジェイソン アボット
クリストス エコノモウ
ステイシー フォス
Original Assignee
カリコ ライフ サイエンシーズ エルエルシー
アッヴィ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カリコ ライフ サイエンシーズ エルエルシー, アッヴィ・インコーポレイテッド filed Critical カリコ ライフ サイエンシーズ エルエルシー
Publication of JP2022522526A publication Critical patent/JP2022522526A/ja
Priority to JP2022209142A priority Critical patent/JP7617890B2/ja
Application granted granted Critical
Publication of JP7204005B2 publication Critical patent/JP7204005B2/ja
Priority to JP2025002163A priority patent/JP2025061064A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021555178A 2019-03-14 2020-03-13 タンパク質チロシンホスファターゼ阻害物質及びその使用方法 Active JP7204005B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022209142A JP7617890B2 (ja) 2019-03-14 2022-12-27 タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP2025002163A JP2025061064A (ja) 2019-03-14 2025-01-07 タンパク質チロシンホスファターゼ阻害物質及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962818447P 2019-03-14 2019-03-14
US62/818,447 2019-03-14
PCT/US2020/022717 WO2020186199A1 (en) 2019-03-14 2020-03-13 Protein tyrosine phosphatase inhibitors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022209142A Division JP7617890B2 (ja) 2019-03-14 2022-12-27 タンパク質チロシンホスファターゼ阻害物質及びその使用方法

Publications (2)

Publication Number Publication Date
JP2022522526A JP2022522526A (ja) 2022-04-19
JP7204005B2 true JP7204005B2 (ja) 2023-01-13

Family

ID=70190226

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021555178A Active JP7204005B2 (ja) 2019-03-14 2020-03-13 タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP2022209142A Active JP7617890B2 (ja) 2019-03-14 2022-12-27 タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP2025002163A Pending JP2025061064A (ja) 2019-03-14 2025-01-07 タンパク質チロシンホスファターゼ阻害物質及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022209142A Active JP7617890B2 (ja) 2019-03-14 2022-12-27 タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP2025002163A Pending JP2025061064A (ja) 2019-03-14 2025-01-07 タンパク質チロシンホスファターゼ阻害物質及びその使用方法

Country Status (24)

Country Link
US (1) US10851073B2 (enExample)
EP (1) EP3938038A1 (enExample)
JP (3) JP7204005B2 (enExample)
KR (2) KR20230074822A (enExample)
CN (2) CN116332873A (enExample)
AR (1) AR118374A1 (enExample)
AU (1) AU2020234712B2 (enExample)
BR (1) BR112021017430A2 (enExample)
CA (1) CA3131894A1 (enExample)
CL (2) CL2021002382A1 (enExample)
CO (1) CO2021013524A2 (enExample)
CR (1) CR20210516A (enExample)
DO (1) DOP2021000188A (enExample)
EC (1) ECSP21075909A (enExample)
IL (2) IL286373B1 (enExample)
MA (1) MA55301A (enExample)
MX (2) MX2021010544A (enExample)
MY (1) MY209419A (enExample)
PE (1) PE20212154A1 (enExample)
PH (1) PH12021552194A1 (enExample)
SG (1) SG11202109067PA (enExample)
TW (2) TWI849082B (enExample)
UY (1) UY38613A (enExample)
WO (1) WO2020186199A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023052094A (ja) * 2019-03-14 2023-04-11 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP2023542503A (ja) * 2020-09-11 2023-10-10 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4077291A1 (en) * 2019-12-18 2022-10-26 Calico Life Sciences LLC Protein tyrosine phosphatase inhibitors and methods of use thereof
IL305072A (en) * 2021-02-12 2023-10-01 Recovery Therapeutics Inc Compounds, compositions, and methods for modulating fgf activity
EP4305030A4 (en) * 2021-03-11 2025-05-21 Kumquat Biosciences Inc. HETEROCYCLES AND THEIR USES
WO2022261145A1 (en) * 2021-06-10 2022-12-15 Ness Therapeutics, Inc. Compounds having 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes
EP4430038A1 (en) * 2021-11-11 2024-09-18 Calico Life Sciences LLC Protein tyrosine phosphatase inhibitors and methods of use thereof
MX2024005656A (es) * 2021-11-11 2024-08-06 Calico Life Sciences Llc Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos.
CA3243580A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics Inc TYROSINE PHOSPHATASE PROTEIN INHIBITORS AND THEIR USES
JP2025507292A (ja) * 2022-02-02 2025-03-18 ネリオ セラピューティクス，インク． プロテインチロシンホスファターゼ阻害剤およびその使用
JP2025505994A (ja) * 2022-02-02 2025-03-05 ネリオ セラピューティクス，インク． プロテインチロシンホスファターゼ阻害剤およびその使用
EP4496797A1 (en) * 2022-03-21 2025-01-29 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
EP4587436A1 (en) * 2022-09-13 2025-07-23 Kumquat Biosciences Inc. Benzo-fused n-heterocycles and uses thereof
WO2024067802A1 (zh) * 2022-09-30 2024-04-04 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
WO2024141015A1 (en) * 2022-12-30 2024-07-04 Insilico Medicine Ip Limited Protein tyrosine phosphatase inhibitors and uses thereof
WO2025011570A1 (zh) * 2023-07-11 2025-01-16 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途
TW202519514A (zh) 2023-07-14 2025-05-16 天主教魯汶大學 新穎化合物(一)
WO2025026158A1 (zh) * 2023-07-28 2025-02-06 杭州中美华东制药有限公司 具有ptpn2抑制作用的化合物及其用途
WO2025030008A1 (en) * 2023-08-02 2025-02-06 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitor combinations
WO2025055985A1 (zh) * 2023-09-15 2025-03-20 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途
CN120004876A (zh) * 2023-11-16 2025-05-16 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
WO2025136841A1 (en) * 2023-12-19 2025-06-26 Merck Sharp & Dohme Llc Substituted isoquinoline derivatives and methods of use thereof
WO2025242216A1 (zh) * 2024-05-24 2025-11-27 杭州百新生物医药科技有限公司 吲哚啉类化合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518419A (ja) 2005-12-08 2009-05-07 ノバルティス アクチエンゲゼルシャフト ＰＴＰａｓｅ阻害剤としての１−オルトフルオロフェニル置換１，２，５−チアゾリジンジオン誘導体
JP2009532379A (ja) 2006-03-31 2009-09-10 ノバルティス アクチエンゲゼルシャフト ＰＴＰａｓｅのチアジアゾリジノン阻害剤
JP2010529075A (ja) 2007-06-04 2010-08-26 ノバルティス アーゲー 抗糖尿病剤としてのチアジアゾール誘導体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
JP4846978B2 (ja) 2001-10-30 2011-12-28 メルク セローノ ソシエテ アノニム タンパク質チロシンホスファターゼのオキシンドールヒドラジンモジュレータ
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
US20100160228A1 (en) 2007-05-23 2010-06-24 Valtion Teknillinen Tutkimuskeskus Method for inhibiting or stimulating angiogenesis in an individual
WO2010008852A2 (en) 2008-06-23 2010-01-21 Taiga Biotechnologies, Inc. Methods of trea fing λλd methods of diagnosing an immunoproliferative disorder
US9217012B2 (en) 2009-04-08 2015-12-22 Indiana University Research And Technology Corporation Inhibitors of protein tyrosine phosphatases
WO2011057331A1 (en) 2009-11-11 2011-05-19 Monash University A method for treating obesity
WO2011094806A1 (en) 2010-02-03 2011-08-11 Monash University Diagnostic and prognostic assay for breast cancer
WO2014068527A1 (en) * 2012-11-02 2014-05-08 Pfizer Inc. Bruton's tyrosine kinase inhibitors
CN106471004A (zh) 2014-02-28 2017-03-01 麦吉尔大学学术发展皇家学院 作为用于免疫疗法的apc活化剂的tc‑ptp抑制剂
US20170224731A1 (en) 2014-06-10 2017-08-10 Monash University Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
CN111303159A (zh) * 2014-10-02 2020-06-19 豪夫迈·罗氏有限公司 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
US20180325925A1 (en) 2015-11-06 2018-11-15 Kyungpook National University Industry-Academic Cooperation Foundation Composition for prevention or treatment of neuroinflammatory disease, containing protein tyrosine phosphatase inhibitor
WO2017078499A2 (ko) 2015-11-06 2017-05-11 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
WO2018148378A1 (en) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
WO2018227248A1 (en) 2017-06-13 2018-12-20 Monash University Methods and compositions for the treatment of obesity
CA3073755A1 (en) 2017-08-24 2019-02-28 The Royal Institution For The Advancement Of Learning/Mcgill Universit Enhancing cd8+ t cells for adoptive cell therapy by inhibiting ptpn1 (ptp1b) and ptpn2 (tc-ptp)
AU2019290197B2 (en) * 2018-06-21 2023-08-24 Abbvie Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
EP3938038A1 (en) 2019-03-14 2022-01-19 Calico Life Sciences LLC Protein tyrosine phosphatase inhibitors and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518419A (ja) 2005-12-08 2009-05-07 ノバルティス アクチエンゲゼルシャフト ＰＴＰａｓｅ阻害剤としての１−オルトフルオロフェニル置換１，２，５−チアゾリジンジオン誘導体
JP2009532379A (ja) 2006-03-31 2009-09-10 ノバルティス アクチエンゲゼルシャフト ＰＴＰａｓｅのチアジアゾリジノン阻害剤
JP2010529075A (ja) 2007-06-04 2010-08-26 ノバルティス アーゲー 抗糖尿病剤としてのチアジアゾール誘導体

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023052094A (ja) * 2019-03-14 2023-04-11 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP7617890B2 (ja) 2019-03-14 2025-01-20 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP2023542503A (ja) * 2020-09-11 2023-10-10 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法

Also Published As

Publication number Publication date
IL286373B1 (en) 2025-11-01
PH12021552194A1 (en) 2022-08-22
SG11202109067PA (en) 2021-09-29
ECSP21075909A (es) 2021-11-30
JP2022522526A (ja) 2022-04-19
PE20212154A1 (es) 2021-11-09
MX2024010859A (es) 2024-09-11
BR112021017430A2 (pt) 2022-01-18
AU2020234712B2 (en) 2025-12-04
IL286373A (en) 2021-10-31
CO2021013524A2 (es) 2022-02-28
CN116332873A (zh) 2023-06-27
MY209419A (en) 2025-07-08
KR20210151821A (ko) 2021-12-14
CL2021002382A1 (es) 2022-06-03
MX2021010544A (es) 2021-10-01
CN114025844A (zh) 2022-02-08
WO2020186199A1 (en) 2020-09-17
KR20230074822A (ko) 2023-05-31
UY38613A (es) 2020-09-30
CN114025844B (zh) 2022-07-26
CR20210516A (es) 2022-07-19
CA3131894A1 (en) 2020-09-17
MA55301A (fr) 2022-01-19
AU2020234712A1 (en) 2021-09-09
TWI849082B (zh) 2024-07-21
AR118374A1 (es) 2021-09-29
TW202519515A (zh) 2025-05-16
US20200299246A1 (en) 2020-09-24
JP2025061064A (ja) 2025-04-10
DOP2021000188A (es) 2022-03-15
JP7617890B2 (ja) 2025-01-20
US10851073B2 (en) 2020-12-01
IL324019A (en) 2025-12-01
CL2024001723A1 (es) 2024-11-22
KR102533599B1 (ko) 2023-05-17
TW202100515A (zh) 2021-01-01
EP3938038A1 (en) 2022-01-19
JP2023052094A (ja) 2023-04-11

Similar Documents

Publication Publication Date Title
JP7204005B2 (ja) タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP7704787B2 (ja) タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法
JP2023542503A (ja) タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP7751582B2 (ja) タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法
RU2833220C2 (ru) Ингибиторы белковых тирозинфосфатаз и способы их применения
RU2799446C2 (ru) Ингибиторы протеин-тирозинфосфатазы и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220325

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221227

R150 Certificate of patent or registration of utility model

Ref document number: 7204005

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150